Syremis Launches with $165M Series A to Advance Schizophrenia and Depression Pipeline

Tel Aviv and Boston, MA, December 18, 2025 (Business Wire) -- Syremis Therapeutics debuted with a $165 million Series A financing to develop best-in-class medicines for severe mental health conditions, led by Dexcel Pharma and Third Rock Ventures. The funding will support clinical proof of concept for ST-905, a dual M1/M4 muscarinic agonist already in Phase 1 for schizophrenia, and advance ST-901, a novel NMDA antagonist for major depressive disorder and bipolar depression toward Phase 1 next year. Syremis’ programs, spun out of Clexio Biosciences, aim to address major unmet needs in neuropsychiatric care with therapies rooted in emerging, clinically validated biology.

Read full article here.